MULTI-STATE MODEL TO ESTIMATE THE OPTIMAL DURATION OF FIRST-LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER: DATA FROM THE NATIONAL REGISTRY AGAMENON
4CPS-105
PRESCRIBED ANTINEOPLASTIC AGENTS IN PAEDIATRIC PATIENTS
4CPS-104
CHEMOTHERAPY TREATMENT IN COLORECTAL CANCER PATIENTS OLDER THAN 70 YEARS AT A TERTIARY HOSPITAL
4CPS-103
EVALUATION OF HEALTH OUTCOMES OF DARATUMUMAB IN MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
4CPS-102
MEASUREMENT OF HEALTH OUTCOMES OF POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE COMBINATION IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
4CPS-101
INTRAVENOUS IMMUNOGLOBULINS USE FOR CHILDREN'S NEUROLOGICAL AND NEURODEVELOPMENTAL DISORDERS
4CPS-100
QUALITY OF INTRATECT: IN VITRO EVALUATION OF BIOLOGICAL ACTIVITIES
4CPS-099
PALIVIZUMAB OFF LABEL USE IN TERTIARY REFERRAL HOSPITAL
4CPS-098
INFLUENCE OF PHARMACOLOGICAL INTERACTIONS IN HEPATITIS C TREATMENT SELECTION IN OPIATE-DEPENDENT PATIENTS
4CPS-097
COBICISTAT INTERACTIONS WITH CHRONIC TREATMENTS
4CPS-096
ABSTRACT WITHDRAWN
4CPS-095
RESCUE OF PATIENTS INFECTED WITH HEPATITIS C VIRUS NOT RESPONDING TO INTERFERON-FREE THERAPIES
4CPS-094
EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR IN REAL-WORLD CLINICAL PRACTICE FOR CHRONIC HEPATITIS C INFECTION
4CPS-093
PERSISTENCE OF AN ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS PATIENTS IN A TERTIARY LEVEL HOSPITAL
4CPS-092
PREVALENCE OF POLYPHARMACY IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION
